|
US4911920A
(en)
|
1986-07-30 |
1990-03-27 |
Alcon Laboratories, Inc. |
Sustained release, comfort formulation for glaucoma therapy
|
|
FR2588189B1
(fr)
|
1985-10-03 |
1988-12-02 |
Merck Sharp & Dohme |
Composition pharmaceutique de type a transition de phase liquide-gel
|
|
JP2594486B2
(ja)
|
1991-01-15 |
1997-03-26 |
アルコン ラボラトリーズ インコーポレイテッド |
局所的眼薬組成物
|
|
US5212162A
(en)
|
1991-03-27 |
1993-05-18 |
Alcon Laboratories, Inc. |
Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
|
|
DE19859684A1
(de)
*
|
1998-12-23 |
2000-06-29 |
Bayer Ag |
Verfahren zur Herstellung von Fluor enthaltenden Phenethylaminen sowie neue, Fluor enthalende beta-Iminovinyl- und beta-Iminoethylbenzole
|
|
JP2002293764A
(ja)
*
|
2001-01-26 |
2002-10-09 |
Takeda Chem Ind Ltd |
アミノエタノール誘導体
|
|
US7267121B2
(en)
|
2004-04-20 |
2007-09-11 |
Aerogen, Inc. |
Aerosol delivery apparatus and method for pressure-assisted breathing systems
|
|
GT200500284A
(es)
*
|
2004-10-15 |
2006-03-27 |
Aventis Pharma Inc |
Pirimidinas como antagonistas del receptor de prostaglandina d2
|
|
WO2006079999A2
(en)
|
2006-04-09 |
2006-08-03 |
Barth Frederik H |
Induction of a novel state of mind with a 5-ht2a agonist and a nmda antagonist
|
|
WO2008016677A2
(en)
|
2006-08-02 |
2008-02-07 |
Auspex Pharmaceuticals, Inc. |
Preparation and utility of deuterated amphetamines
|
|
CN102014995B
(zh)
|
2007-03-30 |
2015-05-13 |
菲利普莫里斯生产公司 |
用于输送药剂的装置和方法
|
|
WO2016040822A1
(en)
*
|
2014-09-12 |
2016-03-17 |
Pinpoint Testing, Llc |
Ready-to-constitute analytical platforms for chemical analyses and quantification
|
|
US11839613B2
(en)
*
|
2017-05-18 |
2023-12-12 |
Idorsia Pharmaceuticals Ltd |
Pyrimidine derivatives as PGE2 receptor modulators
|
|
FI4349407T3
(fi)
|
2019-02-22 |
2025-06-02 |
Gh Res Ireland Limited |
5-metoksi-n,n-dimetyylitryptamiini (5-meo-dmt) vaikean masennuksen hoitoon
|
|
CA3132731A1
(en)
|
2019-03-07 |
2020-09-10 |
University Of Padova |
Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
|
|
US12377112B2
(en)
|
2019-04-17 |
2025-08-05 |
Compass Pathfinder Limited |
Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
|
|
GB201907871D0
(en)
|
2019-06-03 |
2019-07-17 |
Small Pharma Ltd |
Therapeutic compositions
|
|
US20220304980A1
(en)
|
2019-07-04 |
2022-09-29 |
SW Holdings, Inc |
Metered dosing compositions and methods of use of psychedelic compounds
|
|
CN112430187B
(zh)
|
2019-08-07 |
2023-01-17 |
北京奇点势能科技有限公司 |
一种α,β-氘代胺类化合物、氘代药物及其制备方法
|
|
US11246860B2
(en)
|
2019-11-07 |
2022-02-15 |
Lophora ApS |
5-HT2A agonists for use in treatment of depression
|
|
WO2021234608A1
(en)
|
2020-05-19 |
2021-11-25 |
Cybin Irl Limited |
Deuterated tryptamine derivatives and methods of use
|
|
EP3902541B1
(en)
|
2020-06-02 |
2022-09-14 |
Small Pharma Ltd |
Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
|
|
RU199823U1
(ru)
|
2020-06-10 |
2020-09-21 |
Общество С Ограниченной Ответственностью "Центр Передовых Радиационных Медицинских И Биологических Технологий |
Устройство для лечения бронхолегочных заболеваний
|
|
AU2021328671A1
(en)
|
2020-08-18 |
2023-02-16 |
Cybin Irl Limited |
Phenethylamine derivatives, compositions, and methods of use
|
|
EP4221682A2
(en)
|
2020-10-02 |
2023-08-09 |
Cybin IRL Limited |
Methods for delivery of psychedelic medications by inhalation and systems for performing the methods
|
|
CA3206432A1
(en)
|
2021-02-24 |
2022-09-01 |
Mind Medicine, Inc. |
Mescaline derivatives with modified action
|
|
US20220323378A1
(en)
|
2021-04-03 |
2022-10-13 |
Shawn Joseph |
Pharmaceutical Compositions and Methods for Treating Mental Health Disorders and Promoting Neural Plasticity
|
|
WO2022221942A1
(en)
|
2021-04-19 |
2022-10-27 |
Betterlife Pharma Inc. |
Prevention of drug diversion
|
|
WO2022225884A1
(en)
|
2021-04-22 |
2022-10-27 |
Lennham Pharmaceuticals, Inc. |
Deuterated derivatives of psychedelic compounds and uses thereof
|
|
MX2023014630A
(es)
|
2021-06-08 |
2024-01-30 |
Atai Therapeutics Inc |
Activadores de dimetoxifenilalquilamina de receptores de serotonina.
|
|
WO2022271982A1
(en)
|
2021-06-23 |
2022-12-29 |
Synaptive Therapeutics, Llc |
Substituted phenethylamine for treating inflammation and psychological disorders
|
|
EP4366729A4
(en)
|
2021-07-07 |
2025-06-11 |
Arcadia Medicine, Inc. |
SAFER PSYCHOACTIVE COMPOSITIONS
|
|
EP4370114A4
(en)
|
2021-07-14 |
2025-12-24 |
Mydecine Innovations Group Inc |
NEW SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS
|
|
CA3229713A1
(en)
|
2021-08-20 |
2023-02-23 |
Terran Biosciences Inc. |
Deuterated analogs and derivatives of 4-bromo-2,5-dimethoxyphenethylamine and uses thereof
|
|
JP2024533291A
(ja)
|
2021-09-08 |
2024-09-12 |
サイビン アイアールエル リミテッド |
併用薬物療法
|
|
WO2023049480A1
(en)
|
2021-09-25 |
2023-03-30 |
Alexander Shulgin Research Institute |
Substituted phenylalkylamines
|
|
WO2023156453A1
(en)
|
2022-02-15 |
2023-08-24 |
Cybin Irl Limited |
Phenethylamine derivatives, compositions, and methods of use
|
|
EP4479373A1
(en)
|
2022-02-15 |
2024-12-25 |
Cybin IRL Limited |
Therapeutic phenethylamine compositions and methods of use
|
|
CA3246274A1
(en)
|
2022-03-31 |
2023-10-05 |
Cybin Irl Limited |
METHODS OF ADMINISTRATING PSYCHEDELIC MEDICINES BY INHALATION AND SYSTEMS FOR IMPLEMENTING THESE METHODS
|
|
AU2023242469A1
(en)
|
2022-03-31 |
2024-09-05 |
Cybin Irl Limited |
Combination of nitrous oxide and 5-ht2a receptor agonists
|
|
EP4608806A1
(en)
|
2022-10-28 |
2025-09-03 |
Cybin IRL Limited |
Phenethylamine compounds, compositions, and methods of use
|